SGSerena Gianfaldoni

Serena Gianfaldoni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Serena Gianfaldoni has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Biofibre® Artificial Hair Implant : Retrospective Study on 1.518 Patients with alopecia and Present Role in Hair Surgery

    by F. Satolli, M. Rovesti, B. Al Bzour, G. Griselli, M. Agarwal, Aar. Said, S. Gianfaldoni, I. Lozev, I. Pidakev, C. Feliciani, et al.

    To treat alopecia there are many surgical and non‐surgical treatments available nowadays. In the surgical one, the Biofibre® hair implantation system represents an important innovation with artificial hair with special physical, chemical and mechanical features and the new Biofibre® Automatic device. Implant on 1518 patients has been reported in this study where the Biofibre® hair implant technique is performed on men and women with varying degrees of baldness and for the treatment of various causes of alopecia such as androgenetic alopecia, burns and scars. According to our experience, this technique gives immediate and visible results without scarring or hospitalization and the aesthetic results are very encouraging for both male and female patients with a rapid recovery of self‐esteem and psychological well‐being.


  • Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study

    by Sima Rasaii, Nasibe Sohrabian, Serena Gianfaldoni, Maryam Hadibarhaghtalab, Nader Pazyar, Alireza Bakhshaeekia, Torello Lotti, Luis A. Ramirez‐Pacheco, Christopher S. Lange, Jaime Matta, et al.

    Cutaneous injury can ignite excessive fibroproliferative growth that results in keloid formation. Keloids are associated with significant morbidity related to disfigurement and/or symptoms (e.g. pain, pruritus). First‐line treatment of formed keloids involves topical or intralesional steroids. Recurrent or resistant keloids are managed by surgical excision or cryotherapy, followed by steroidal application or adjuvant irradiation. While adjuvant irradiation appears to be most efficacious, alternative therapeutic options are needed for patients without access to radiation centers. Botulinum Toxin A (BTA) appears to have similar inhibitory effects to irradiation on the cell cycle via downregulation of pathogenic cytokines. Herein, we conducted a study to compare the efficacy of intralesional triamcinolone used alone, or in combination with BTA, in the treatment of formed keloid scars. 20 patients with a cumulative of 40 keloids completed the study. There was no significant difference between treatment arms with respect to height vascularization, pliability and pigmentation scores. The addition of BTA resulted in significant symptomatic improvement of pain and pruritus as compared to intralesional triamcinolone alone (P<0.001). Irradiation is only effective when administered in the adjuvant setting where inhibitory effects on cell cycle and migration are optimized. Future studies with intralesional triamcinolone and BTA should be performed adjuvantly.


  • Controversial issues in vitiligo patients: a review of old and recent treatments

    by Torello Lotti, Serena Gianfaldoni, Yan Valle, Miriam Rovesti, Claudio Feliciano, Francesca Satolli

    Vitiligo is quite a common hypopigmentary disorder, which may affect both children and adults with important psychological effects due to the well‐known leopard skin‐like appearance. The authors summarize in this paper the published evidence on vitiligo with particular interest on the controversial aspects of the disease, such its definition and the available treatments.


  • Open Access

    Is HPV vaccination of pregnant women really safe?

    by Amir Feily, Torello Lotti, Christopher S. Lange, Serena Gianfaldoni, Marigdalia K. Ramirez‐Fort